Search Results
Your search for ,loW matches 7101 pages
Showing 1451 - 1500Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial were...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...
Xuesong Han, PhD, on Medicaid Expansion and Receipt of Palliative Care Among Individuals Newly Diagnosed With Advanced-Stage Cancers
Xuesong Han, PhD, of the American Cancer Society, discusses findings showing that among newly diagnosed patients with stage IV cancers, Medicaid expansion was associated with increases in receipt of palliative care, although overall usage was low. The increase varied by cancer type. Improving...
Incidence of Neurologic Side Effects From CAR-T Cell Therapy Is Higher in Patients With Hypophosphatemia, Study Finds
Patients with B-cell malignancies who had hypophosphatemia experienced a higher incidence and severity of neurologic side effects from chimeric antigen receptor (CAR) T-cell therapy, according to a study by Nowicki et al published in Cancer Immunology Research. The study results imply that...
Intensive Chemoresection With Mitomycin to Reduce the Need for Surgical Procedures in Patients With Recurrent Non–Muscle-Invasive Bladder Cancer
In a Danish study (DaBlaCa-13) reported in the Journal of Clinical Oncology, Lindgren et al found that short-term intensive chemoresection with mitomycin reduced the need for surgical procedures in patients with recurrent non–muscle-invasive bladder cancer. Study Details The trial was conducted at...
Study Identifies How Cancer-Causing Gene Might Regulate Genetic Variation in Prostate Cancer
Researchers at the Barts Cancer Institute at the Queen Mary University of London, the Italian Institute for Genomic Medicine, and the University of Milan may have identified a novel role for a cancer-causing gene in controlling an important genetic process that underpins genetic variation in...
ASCO Launches Webinar Series to Close the Global Divide Between Survivorship and Palliative Care in Breast Cancer
In honor of Breast Cancer Awareness Month and World Hospice & Palliative Care Day, ASCO and its partners—the International Association for Hospice & Palliative Care; Tómatelo a Pecho, A.C.; the University of Miami Sylvester Comprehensive Cancer Center and Institute for Advanced Study of the ...
Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the TUXEDO-1 trial1 was Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona. Dr. Oliveira noted that 40% of the 15 patients in TUXEDO-1 had symptomatic disease, and 60% had central nervous system metastases...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Expert Point of View: Patricia LoRusso, DO, PhD
Invited discussant Patricia LoRusso, DO, PhD, of Yale School of Medicine, said to the assembled audience at the 2022 ASCO Annual Meeting: “I see you are as excited about these data as I am,” after the applause ended following Dr. Modi’s presentation. “I want to thank our colleagues for helping to...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer
Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...
Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer
Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast Cancer ...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer
The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer
Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index. The latest findings were reported at a ...
Recent FDA Approvals in Breast Cancer
In the past year, the U.S. Food and Drug Administration (FDA) approved four treatment options for patients with breast cancer, which are summarized herein. T-DXd for HER2-Low Breast Cancer On August 5, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) for adult patients with...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Eligibility for Lung Cancer Screening Among Women With a Smoking History Undergoing Breast Cancer Screening
In a single-center retrospective cohort study reported in JAMA Network Open, Titan et al identified the proportion of women with a history of smoking undergoing breast cancer screening with mammography who were eligible for low-dose computed tomography (CT) lung cancer screening, as well as the...
Study Finds Cost of Cancer Care May Impact Health of Low-Income Survivors
The cost of cancer treatment may negatively impact the physical and mental health of survivors who are living in poverty, according to a recent study published by Coughlin et al in the Journal of Oncology Practice. The findings provide important information about the impact social determinants may...
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
ASCO and the African Organisation for Research and Training in Cancer Announce Innovative Collaboration to Advance Cancer Research in Africa
ASCO and the African Organisation for Research and Training in Cancer (AORTIC) have signed a memorandum of understanding (MOU) committing the two organizations to collaborate to advance cancer research in Africa. Harnessing the respective programs, leaders, and member networks of both...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD
TROPiCS-02 is a statistically positive trial, with the primary endpoint met and also now with an overall survival gain of 3.2 months,” said the study’s invited discussant Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology, Barcelona. “TROPiCS-02 is...
TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
Cancer and Fertility Preservation: Will New Laws Leave Patients Without Options?
The legal climate surrounding reproductive health care and fertility preservation has changed drastically since the June 2022 Supreme Court decision to overturn Roe v Wade, which revoked the constitutional right to abortion. With this ruling, individual state legislatures are now able to pass laws...
Living With Metastatic Breast Cancer
After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...
Medicaid Expansion and Palliative Care Use Among Patients Newly Diagnosed With Advanced Cancer
Recent data showed that Medicaid expansion may be associated with increased use of palliative care among newly diagnosed individuals with stage IV cancer, although overall usage of palliative care was low. In addition, the increase after Medicaid expansion varied by cancer type, according to a...
Toxicity Outcomes With Stereotactic Ablative Radiotherapy for Patients With Up to Five Oligometastases
As reported in JAMA Oncology by Olson et al, the primary toxicity results of the phase II SABR-5 trial have shown a low rate of toxic effects with stereotactic ablative radiotherapy (SABR) for patients with up to five oligometastases. As stated by the investigators: “After the publication of the...
Symptom Clusters in Adult Survivors of Childhood Cancer
In a report from the St. Jude Lifetime Cohort Study population reported in the Journal of Clinical Oncology, Shin et al identified symptom clusters among adult survivors of childhood cancer and potential associations with health-related quality of life and physical and neurocognitive performance....
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
In a single-institution study reported in JAMA Oncology, Allen S. Ho, MD, and colleagues found evidence that active surveillance may be a suitable treatment for most patients with low-risk papillary thyroid carcinoma. Study Details The prospective study included 222 patients enrolled at...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, a thoracic radiologist at Royal Brompton and Harefield hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, noted that both the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial...
NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits
Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the...
NADIM II Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the...
Expert Point of View: Jean-Yves Blay, MD, PhD
The invited discussant of the DeFi trial was Jean-Yves Blay, MD, PhD, General Director of the Center Bérard, Lyon, France, and President of Unicancer, the French Federation of Cancer Centers. He called the DeFi study a “rigorous trial” in a “representative population” that “introduces a new class...
Managing the Risk of Thrombosis in Polycythemia Vera
This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months. In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
2-Year Toxicity With Conventional IMRT vs Hypofractionated SBRT for Localized Prostate Cancer
As reported in The Lancet Oncology by Tree et al, an analysis from the phase III PACE-B trial has shown no difference in 2-year genitourinary or gastrointestinal toxicity with conventionally fractionated/moderately hypofractionated intensity-modulated radiotherapy (IMRT) vs highly hypofractionated...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce...
Financial Burden of High-Cost Targeted Oral Anticancer Drugs Among Medicare Patients
In a study reported in JCO Oncology Practice, Li et al identified elements of increasing financial burden associated with the use of high-cost targeted oral anticancer drugs among Medicare patients between 2011 and 2016. The study used data from the Surveillance, Epidemiology, and End Results...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, a thoracic radiologist at Royal Brompton and Harefield hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, noted that both the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial...
